Cell infusions (intravenous or direct injection) are minimally invasive and cause few acute side effects; patients typically leave the same day. Biochemical changes in bone remodelling unfold over weeks to months, so meaningful clinical assessment requires 3–6 months minimum, with optimal evaluation at 12–18 months.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
我是候选人吗？ → · Osteoporosis & Bone Health: full overview → · 骨质疏松症和骨骼健康成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估